MARGARET AUSTIN: Open Payments
NPI 1598131765 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,461 in 37 payments from 14 companies in 2025. Trend: 2023 $1,334 · 2024 $845 · 2025 $1,461
Food & beverage: $1,461
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $341 |
| Lilly USA, LLC | 11 | $212 |
| Madrigal Pharmaceuticals | 2 | $157 |
| AstraZeneca Pharmaceuticals LP | 1 | $135 |
| BETA BIONICS, INC. | 1 | $119 |
| Dexcom, Inc. | 1 | $118 |
| BridgeBio Pharma, Inc. | 1 | $109 |
| Amgen Inc. | 5 | $93 |
| Xeris Pharmaceuticals, Inc. | 3 | $56 |
| Globus Medical, Inc. | 2 | $31 |
Products named: Ozempic, MOUNJARO, REZDIFFRA, Wegovy, FARXIGA, iLet Bionic Pancreas, DEXCOM G7 GSS (161), Attruby.
Industry payments across MD — which companies pay providers there.
